Danaher Corporation
A global science and technology company serving biotechnology, life sciences, and diagnostic markets.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Danaher Corporation is a United States-based science and technology company headquartered in Washington, D.C. Its principal activities are concentrated in biotechnology, life sciences, and diagnostics. The company develops instruments, consumables, software, services, and production technologies used by pharmaceutical and biotechnology companies, research laboratories, hospitals, clinical laboratories, and other healthcare organizations. Danaher's business model has historically combined acquisitions with disciplined operating management. Rather than functioning as a single consumer-facing product brand, it operates a portfolio of specialized companies and brands. Many of these businesses occupy technically demanding niches, including bioprocessing, genomics, flow cytometry, microscopy, mass spectrometry, molecular diagnostics, clinical chemistry, immunoassay, and laboratory automation. The portfolio approach allows Danaher to serve customers across the development and production cycle for medicines and vaccines, as well as the detection and monitoring of disease. The company traces its corporate origins to DMG, Inc., a Massachusetts real estate investment trust organized in 1969. Steven and Mitchell Rales invested in the business in the early 1980s, took control after a proxy contest, and reorganized it under the Danaher name in 1984. The name was inspired by Danaher Creek in western Montana, where the brothers developed the idea for the company while fishing. Danaher initially expanded through industrial, environmental, measurement, and professional-tool businesses before progressively building a major healthcare and life-science portfolio. Important acquisitions shaped the modern company. Hach established a substantial water-analysis business; Leica Microsystems expanded its microscopy and imaging capabilities; Beckman Coulter strengthened clinical diagnostics and laboratory science; Pall added filtration, separation, and bioprocessing technologies; Cepheid brought molecular diagnostic systems; Integrated DNA Technologies added synthetic nucleic-acid products; and the acquisition of General Electric's biopharma business created Cytiva. Danaher also acquired Aldevron, a supplier of plasmid DNA, mRNA, proteins, and related materials used in advanced therapies and vaccine development, and Abcam, a major provider of research antibodies and protein-related tools. Danaher has also repeatedly reshaped its portfolio through divestitures and separations. The 2016 spin-off of Fortive separated many industrial and professional-tool activities from the core company. Its dental business was later separated into Envista Holdings Corporation. Environmental and applied-solutions activities were separated into Veralto in 2023, leaving Danaher more focused on biotechnology, life sciences, and diagnostics. The company describes these activities through operating groups that include biotechnology, life sciences, and diagnostics. In the 2024 business mix cited in the reference material, diagnostics represented about 41% of revenue, life sciences about 31%, and biotechnology about 28%; these percentages are time-specific and should not be treated as permanent segment weights. Danaher's customers generally purchase specialized capital equipment, recurring consumables, reagents, software, maintenance, and services. Its products support pharmaceutical research, drug discovery, biomanufacturing, gene-editing workflows, laboratory testing, cancer and infectious-disease diagnosis, and quality control. The company is therefore primarily an institutional and business-to-business technology supplier rather than a consumer brand. Its competitive positioning rests on technical specialization, installed equipment bases, recurring consumables, regulatory and application expertise, and the integration of acquired businesses through the Danaher Business System, an operating framework associated with continuous improvement and performance management. Dan…
History
Danaher's corporate history began with DMG, Inc., a Massachusetts real estate investment trust organized in 1969. The entity was reorganized as a Florida corporation in 1978 and was then associated with retirement-home development. Steven M. Rales and Mitchell P. Rales invested in the company in 1983 and gained control after a contested proxy battle. In 1984, the company adopted the Danaher name and reincorporated in Delaware. The name referred to Danaher Creek in Montana, where the brothers conceived the business idea. The early company pursued a broad acquisition strategy. It unsuccessfully bid for Scott Fetzer in 1985, losing to Berkshire Hathaway, and acquired control of Chicago Pneumatic in 1986. Danaher subsequently sold Chicago Pneumatic while retaining Jacobs Manufacturing and its Matco Tools operation. During the late 1980s and 1990s, the company built a collection of industrial, measurement, controls, and professional-tool businesses. Acquisitions included Easco Hand Tools, Armstrong Tools, Hengstler, and other instrumentation companies. Hengstler, acquired in 1995, was Danaher's first acquisition headquartered outside the United States. The acquisition of Hach Company in 1999 added water and wastewater analysis and became an important foundation for Danaher's environmental portfolio. H. Lawrence Culp Jr., who had joined Danaher in 1990, became chief executive in 2000. Under his leadership, the company continued moving toward specialized technology businesses. It acquired Trojan Technologies, West Instruments, PMA, Leica Microsystems, Vision Systems, ChemTreat, and Tektronix. The 2007 purchase of Tektronix for approximately $2.85 billion was one of the period's largest transactions. Danaher also acquired analytical-technology assets from MDS and later purchased the remaining interest in AB SCIEX. The 2011 acquisition of Beckman Coulter was a major step into clinical diagnostics and laboratory science. Danaher later acquired or expanded businesses in dental imaging, fleet technology, dental products, life-science analysis, and bioprocessing. It acquired Nobel Biocare in 2014 and Pall Corporation in 2015. Culp left the chief executive role in 2015, and Thomas Joyce Jr. succeeded him. In 2016, Danaher spun off many industrial activities into Fortive, while also acquiring Cepheid and Phenomenex. The Fortive separation marked a decisive shift away from the older industrial conglomerate structure. Danaher continued building its life-science platform with acquisitions such as ID Business Solutions and Integrated DNA Technologies. In 2018, it announced plans to separate the dental business; the transaction was completed in 2019 with the creation of Envista Holdings Corporation. In 2020, Danaher acquired General Electric's biopharma business for approximately $21.4 billion and renamed it Cytiva. The transaction attracted antitrust scrutiny, and certain assets were sold to Sartorius as part of the regulatory process. In the same year, Joyce retired and Rainer Blair became chief executive. The 2020s brought further concentration in biotechnology and advanced therapeutics. Cytiva acquired Precision Nanosystems in 2021, while Danaher acquired Aldevron for approximately $9.6 billion. Pall and Cytiva were combined into a biotechnology group in 2023. Danaher also separated its environmental and applied-solutions segment into Veralto, completing that spin-off in September 2023. The remaining portfolio was consequently centered on biotechnology, life-science tools, and diagnostics. Abcam joined the company in December 2023, adding a large research-antibody and protein-tools business. In 2024, Cepheid received U.S. marketing authorization for a rapid hepatitis C test, and Danaher acquired GeneData. Danaher's development has therefore progressed from diversified real estate and industrial holdings to a specialized global healthcare technology group built around recurring scientific workflows and mission-critical laboratory products.
- 2023
Veralto is separated
[1]Environmental and applied-solutions businesses are spun off as Veralto.
- 2023
Abcam is acquired
[1]Danaher adds a major research-antibody and protein-tools business.
- 2021
Aldevron is acquired
[1]The acquisition adds DNA, mRNA, and protein inputs for vaccines and advanced therapies.
- 2020
Cytiva is created
[1]Danaher completes the acquisition of GE's biopharma business and rebrands it Cytiva.
- 2019
Envista spin-off is completed
[1]Danaher's dental segment becomes the separately listed Envista Holdings Corporation.
- 2018
Integrated DNA Technologies is acquired
[1]Danaher expands into synthetic DNA and genomics-related research products.
- 2016
Fortive is spun off
[1]Industrial and professional-tool businesses are separated into Fortive.
- 2015
Pall Corporation is acquired
[1]The transaction adds filtration, separation, and bioprocessing technologies.
- 2011
Beckman Coulter joins Danaher
[1]The acquisition expands Danaher's diagnostic and life-science instrument operations.
- 2007
Tektronix is acquired
[1]Danaher buys Tektronix in a transaction valued at approximately $2.85 billion.
Products and positioning
A focused, acquisition-led science and technology group providing mission-critical tools and consumables for biotechnology, life-science research, biopharmaceutical manufacturing, and clinical diagnostics.
Biotechnology and bioprocessing · 2020
Cytiva
Cytiva supplies technologies used to develop, scale, manufacture, and purify biologic medicines, vaccines, cell therapies, and gene therapies. Its portfolio includes filtration, chromatography, single-use systems, cell-culture equipment, and related process-development tools. The business was formed from Danaher's acquisition of GE's biopharma operations and was later combined organizationally with Pall's biotechnology activities.
Molecular diagnostics
Cepheid GeneXpert
GeneXpert is a molecular diagnostic platform designed to automate sample preparation, nucleic-acid amplification, and result interpretation. It supports tests for infectious diseases and other conditions, using instrument systems and disposable cartridges. The platform is intended for clinical laboratories and decentralized testing environments where relatively rapid molecular results are valuable.
Clinical diagnostics · 2011
Beckman Coulter Diagnostics
Beckman Coulter Diagnostics provides analyzers, reagents, automation, software, and workflow services for clinical laboratories. Its activities cover areas such as clinical chemistry, immunoassay, hematology, and laboratory automation. The business became part of Danaher through the 2011 acquisition of Beckman Coulter.
Microscopy and imaging · 2005
Leica Microsystems
Leica Microsystems develops microscopy, imaging, measurement, and analysis systems for research, medicine, and industrial quality applications. Its products support cellular and tissue observation, surgical and laboratory workflows, and materials analysis. Danaher acquired the company in 2005.
Genomics and synthetic biology · 2018
Integrated DNA Technologies
Integrated DNA Technologies supplies custom nucleic-acid products and related tools used in genomics, molecular biology, diagnostics development, and gene-editing research. Its offerings serve academic, biotechnology, pharmaceutical, and diagnostics customers. Danaher acquired the company in 2018.
Advanced therapeutics materials · 2021
Aldevron
Aldevron manufactures plasmid DNA, mRNA, proteins, and related materials used in vaccine research, gene therapy, cell therapy, and other advanced-biotechnology applications. Its products are primarily supplied to research, clinical-development, and biopharmaceutical manufacturing customers.
Research reagents · 2023
Abcam
Abcam develops and supplies research antibodies, proteins, assays, and related reagents used in biological and medical research. The business supports workflows involving protein detection, disease research, drug discovery, and biomarker investigation. Danaher acquired Abcam in 2023.
Brand decisions
2023
Separate environmental and applied-solutions businessesStrategyBackground
Danaher planned to focus its remaining portfolio more narrowly on biotechnology, life sciences, and diagnostics.
Action taken
The environmental and applied-solutions segment was separated into Veralto, with the spin-off completed in September 2023.
Aftermath
Danaher's portfolio became more clearly centered on healthcare, laboratory science, and biopharmaceutical technologies.
2020
Acquire GE Biopharma and establish CytivaM&ABackground
Danaher sought to expand its position in biopharmaceutical development and manufacturing technologies.
Action taken
Danaher acquired General Electric's biopharma business for approximately $21.4 billion and rebranded it Cytiva.
Aftermath
Regulatory review led to the sale of selected biotechnology assets to Sartorius, while Cytiva became a central Danaher biotechnology platform.
Transaction value. $21.4 billion (2020)
2016
Separate industrial activities through the Fortive spin-offStrategyBackground
Danaher had accumulated substantial industrial, controls, measurement, and professional-tool operations alongside its healthcare businesses.
Action taken
The company completed a corporate separation that placed many industrial businesses, including Matco-related operations, into Fortive.
Aftermath
Danaher became more concentrated on life sciences, diagnostics, biotechnology, and related healthcare technologies.
Recent events
Danaher reports quarterly earnings[3]
Reported:
Danaher announced quarterly earnings results on Tuesday, reporting earnings per share of $2.11, which beat the consensus estimate of $1.92 by $0.19.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
Anthropic launches Model Hardware Standard (MHS) for AI agents to control physical hardware[4]
Reported:
Anthropic announced the Model Hardware Standard (MHS), a new standard that lets large-model-driven AI agents such as Claude safely and quickly operate physical devices including microscopes, robotic arms, liquid handlers and lasers. MHS was developed from a collaboration with the Howard Hughes Medical Institute (HHMI) Janelia Research Campus and is available as a research preview to a first group of research labs and advanced manufacturers. Hardware and software vendors including AWS, Automata, Danaher, Doosan Robotics, MBF Bioscience, QIAGEN, Tecan, Universal Robots, Hugging Face and Raspberry Pi are adding or testing MHS support.
Genedata launches Biomarker Discovery Agent in Genedata Profiler[5]
Reported:
Genedata, a Danaher company, announced a new AI agent in Genedata Profiler, its enterprise platform for integrating and analyzing translational and clinical research data, expanding AI-driven biomarker discovery capabilities. In collaboration with Washington University School of Medicine in St. Louis, the agent was used to identify a five-protein blood-based model for Alzheimer's disease validated in an independent cohort.
Danaher globally launches medical-device UDI solution[6]
Reported:
Danaher's product identification platform completed the global launch of its medical-device Unique Device Identification (UDI) solution at the China International Import Expo.
Danaher completes acquisition of Aldevron[7]
Reported:
Danaher Corporation announced completion of its acquisition of Aldevron. Aldevron will operate as a standalone operating company and brand within Danaher's Life Sciences segment.
Danaher announces planned acquisition of Aldevron[8]
Reported:
Danaher announced a definitive agreement to acquire Aldevron for $9.6 billion. The transaction was subject to customary conditions, including regulatory approvals.
Danaher appoints Rainer M. Blair president and CEO[9]
Reported:
Danaher appointed Rainer M. Blair as president and chief executive officer and as a member of its board, effective September 1, 2020. His predecessor, Thomas P. Joyce, Jr., retired from those positions.
Danaher announces Rainer Blair as CEO successor[10]
Reported:
Danaher announced that Executive Vice President Rainer Blair would succeed Thomas Joyce Jr. as President and Chief Executive Officer effective September 1. Blair was also set to join the board, while Joyce would continue as a senior advisor through February 28, 2021.
Danaher completes acquisition of GE Life Sciences’ biopharma business[11]
Reported:
Danaher announced that it had completed its acquisition of the biopharma business from General Electric Company’s Life Sciences division. The acquired business will operate as a standalone company within Danaher’s Life Sciences segment.
Danaher prices $4 billion senior notes offering[12]
Reported:
Danaher announced that its wholly owned subsidiary priced a senior notes offering totaling $4 billion; the company anticipated using net proceeds to fund part of its acquisition of GE Life Sciences' Biopharma Business and related costs.
Showing the 10 most recent.
Sources17 sources
- 1Danaher Corporationen.wikipedia.org
- 2Danaher official websitedanaher.com
- 3Danaher公布季度业绩themarketsdaily.com
- 4Anthropic发布面向AI智能体操控物理硬件的Model Hardware Standard（MHS）finance.sina.com.cn
- 5Genedata在Genedata Profiler中推出生物标志物发现AI代理prnewswire.com
- 6丹纳赫全球首发医疗器械UDI解决方案prnasia.com
- 7Danaher 完成对 Aldevron 的收购prnewswire.com
- 8Danaher宣布计划收购Aldevroninforum.com
- 9Danaher任命Rainer M. Blair为总裁兼首席执行官prnewswire.com
- 10Danaher 宣布 Rainer Blair 将接任首席执行官finanznachrichten.de
- 11Danaher完成对GE生命科学生物制药业务的收购prnewswire.com
- 12Danaher为40亿美元优先票据发行定价prnewswire.com
- 13丹纳赫宣布向Sartorius出售部分生命科学业务finance.sina.com.cn
- 14丹纳赫宣布收购生物技术公司Aldevron，加码基因治疗领域prnasia.com
- 15Anthropic launches framework for AI agents to operate devicesbignewsnetwork.com
- 16Anthropic launches Model Hardware Standard for AI agentsthehindubusinessline.com
- 17Danaher Announces Pricing Of Senior Notes Offeringprnewswire.com
Cite this profile: Cite the canonical profile. /brand-wiki/danaher-corporation · Editorial policy · How profiles are compiled